0.065 -0.098 (-60.05%) | 12-12 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 0.07 | 1-year : | 0.08 |
Resists | First : | 0.06 | Second : | 0.07 |
Pivot price | 0.06 | |||
Supports | First : | 0.06 | Second : | 0.06 |
MAs | MA(5) : | 0.06 | MA(20) : | 0.06 |
MA(100) : | 0.87 ![]() |
MA(250) : | 2.3 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 0 | D(3) : | 1 |
RSI | RSI(14): 20.2 | |||
52-week | High : | 11 | Low : | 0.06 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TFFP ] has closed above bottom band by 50.0%. Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 46 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.07 - 0.07 | 0.07 - 0.07 |
Low: | 0.06 - 0.06 | 0.06 - 0.06 |
Close: | 0.06 - 0.07 | 0.07 - 0.07 |
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.
Thu, 06 Feb 2025
TFF Pharmaceuticals to Exit Nasdaq: Complete Liquidation Plan Leaves Shareholders in Limbo - StockTitan
Thu, 06 Feb 2025
TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration - Yahoo Finance
Tue, 10 Dec 2024
TFF Pharmaceuticals to be delisted from Nasdaq - Investing.com
Wed, 20 Nov 2024
TFF Pharmaceuticals Inc - Ordinary Shares (TFFP) reports earnings - Quartz
Fri, 15 Nov 2024
ARMISTICE CAPITAL, LLC Acquires Shares in TFF Pharmaceuticals Inc - GuruFocus.com
Thu, 14 Nov 2024
TFF Pharmaceuticals terminates employees, to wind down operations - Nasdaq
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 4 (M) |
Shares Float | 3 (M) |
Held by Insiders | 3.3 (%) |
Held by Institutions | 24.3 (%) |
Shares Short | 172 (K) |
Shares Short P.Month | 131 (K) |
EPS | -5.5 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 4.03 |
Profit Margin | 0 % |
Operating Margin | -609.5 % |
Return on Assets (ttm) | -106 % |
Return on Equity (ttm) | -213.6 % |
Qtrly Rev. Growth | 95 % |
Gross Profit (p.s.) | -2.3 |
Sales Per Share | 0.27 |
EBITDA (p.s.) | -4.29 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -14 (M) |
Levered Free Cash Flow | -6 (M) |
PE Ratio | -0.02 |
PEG Ratio | 0 |
Price to Book value | 0.01 |
Price to Sales | 0.24 |
Price to Cash Flow | -0.03 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |